Company Profile
MacroGenics Stock Price, News & Catalysts
- Ticker:
- MGNX
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
2.22 USD (-3.90%)
Close
Last updated: November 5, 2026
257M USD
Market cap
Why the stock is moving
The latest monitored company update is “MacroGenics to Participate in Upcoming Investor Conferences.” The corresponding closing-price reaction is not yet available.
Company overview
Antibody Engineering Company
MacroGenics develops antibody-based cancer therapies using internal platforms for monoclonal antibodies, bispecific molecules, and antibody-drug conjugates.
ADC Portfolio
MGC026 targets B7-H3 and is in Phase 1 dose expansion, while MGC028 targets ADAM9 and is in Phase 1 dose escalation across advanced solid tumors.
Lorigerlimab Program
Lorigerlimab is a bispecific DART molecule designed to block PD-1 and CTLA-4, with preferential activity in the tumor microenvironment. The Phase 2 LINNET study is evaluating the candidate as monotherapy in advanced clear-cell gynecologic cancers and other difficult-to-treat tumors.
Focused R&D Model
Following divestiture of its manufacturing operation, MacroGenics is concentrating resources on drug discovery, clinical development, partnerships, and royalty interests such as ZYNYZ.
Future catalysts
- Updated results from the Phase 2 LINNET study of lorigerlimab in clear-cell gynecologic cancers in the first half of 2027.
Recent news
- 01
- 02
- 03
- 04
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of MacroGenics (MGNX)?
MacroGenics (MGNX) most recently closed at 2.22 USD, a -3.90% move versus the previous session.
What is the market cap of MacroGenics (MGNX)?
MacroGenics currently has a market capitalization of 257M USD on BioPharmSignal.
What does MacroGenics do?
Antibody Engineering Company MacroGenics develops antibody-based cancer therapies using internal platforms for monoclonal antibodies, bispecific molecules, and antibody-drug conjugates. ADC Portfolio MGC026 targets B7-H3 and is in Phase 1 dose expansion, while MGC028 targets ADAM9 and is in Phase 1 dose escalation across advanced solid tumors. Lorigerlimab...
On which exchange is MGNX stock listed?
MacroGenics (MGNX) is associated with NASDAQ, United States, Biopharma.
What is PD-1?
Lorigerlimab Program Lorigerlimab is a bispecific DART molecule designed to block PD-1 and CTLA-4, with preferential activity in the tumor microenvironment.
Which conditions is MacroGenics targeting with PD-1?
MacroGenics is associated with cancer therapeutics based on its company overview and current catalyst commentary.
How does MacroGenics describe recent progress with PD-1?
Updated results from the Phase 2 LINNET study of lorigerlimab in clear-cell gynecologic cancers in the first half of 2027.
What is CTLA-4?
Lorigerlimab Program Lorigerlimab is a bispecific DART molecule designed to block PD-1 and CTLA-4, with preferential activity in the tumor microenvironment.